AEON Biopharma Files 2024 10-K, Details Financials
Ticker: AEON · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1837607
Sentiment: neutral
Topics: 10-K, financials, biopharma
TL;DR
AEON Bio's 2024 10-K is in. Cash is $5M, assets $3M. Fair value adjustments on warrants/derivatives noted.
AI Summary
AEON Biopharma, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Priveterra Acquisition Corp., reported various financial figures including $5.0 million in cash and cash equivalents and $3.0 million in total assets. The filing also details changes in the fair value of derivative instruments and warrants, with specific inputs like share price and risk-free interest rates noted for December 31, 2024.
Why It Matters
This filing provides investors with a comprehensive overview of AEON Biopharma's financial health and operational status as of the end of 2024, crucial for understanding its current market position and future prospects.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often carry higher risk due to the inherent uncertainties in drug development, regulatory approvals, and market adoption.
Key Numbers
- $5.0M — Cash and Cash Equivalents (Indicates liquidity as of December 31, 2024.)
- $3.0M — Total Assets (Represents the company's total assets as of December 31, 2024.)
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
Key Players & Entities
- AEON Biopharma, Inc. (company) — Filer of the 10-K
- Priveterra Acquisition Corp. (company) — Former name of AEON Biopharma, Inc.
- December 31, 2024 (date) — Fiscal year end for the report
- $5.0 million (dollar_amount) — Cash and cash equivalents
- $3.0 million (dollar_amount) — Total assets
FAQ
What was AEON Biopharma's cash and cash equivalents balance as of December 31, 2024?
As of December 31, 2024, AEON Biopharma, Inc. reported cash and cash equivalents of $5,000,000.
What were the total assets of AEON Biopharma as of the end of the fiscal year 2024?
The total assets for AEON Biopharma, Inc. as of December 31, 2024, were $3,000,000.
What was the previous name of AEON Biopharma, Inc.?
AEON Biopharma, Inc. was formerly known as Priveterra Acquisition Corp., with a name change date of December 22, 2020.
What specific financial inputs were used for fair value measurements on December 31, 2024?
On December 31, 2024, key inputs for fair value measurements included share price, risk-free interest rate, price volatility, and expected term.
What is the Standard Industrial Classification (SIC) code for AEON Biopharma, Inc.?
AEON Biopharma, Inc. is classified under SIC code 2834, which pertains to Pharmaceutical Preparations.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding AEON Biopharma, Inc. (AEON).